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Abstract
Background:  Few published reports have evaluated the clinical features and outcome of
serogroup W135 meningococcal disease. In Taiwan, W135 is the second most prevalent
meningococcal disease serogroup.
Method: A nationwide study was conducted to retrospectively analyze epidemiologic data from
115 patients with laboratory confirmed meningococcal disease that occurred from 2001 through
2003.
Results: Serogroup W135 accounted for 26% of all cases and most (76.7%) were older than 20
years. There were no cases of serogroup W135 meningococcal disease associated with Hajj
pilgrims, and all cases were sporadic. In 88 patients with complete case records, we compared the
presenting symptoms, signs, laboratory data, and outcomes between W135 and non-W135
patients. There were no differences in presenting symptoms except for the higher prevalence of
pneumonia found in W135 patients (23.8% vs. 1.5%; OR: 20.6; 95%CI: 2.3–189.0; p = 0.003). The
distribution of inflammatory cells in CSF in patients with meningitis was also different between
W135 and non-W135 patients. W135 patients had a trend toward more intubations and shock but
it did not achieve statistical significance. In multivariate analysis of factors associated with death,
three independent factors were found: bacteremia without meningitis, altered mental status, and
petechiae or purpura on admission.
Conclusion: Sporadic serogroup W135 meningococcal disease is an important component of the
meningococcal disease burden in Taiwan, but it is not directly associated with Hajj pilgrims.
Compared with patients infected by other serogroups of meningococci, patients with serogroup
W135 were older and more likely to have extrameningeal involvement such as pneumonia.
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Background
Previous surveys of meningococcal disease in the United
States and elsewhere found serogroup W135 was rare [1].
An outbreak of serogroup W135 meningococcal infection
in Saudi Arabia following the 2000 Hajj was reported, and
then spread to several countries around the world [2-4].
Significantly higher carriage rate of N. meningitidis sero-
group W135 in pilgrims returning from the Hajj [5,6] and
continuing diversification of the serogroup after its emer-
gence in 2000 has been found [7,8]. In Taiwan, only
about 2% (50,000) of the population are Muslims. In the
period from 2001 through 2003, about 20 to 40 pilgrims
per year went from Taiwan to Saudi Arabia for the Hajj
(data from Chinese Muslim Association, Taiwan). Little is
known about the clinical features and outcome of sero-
group W135 disease [9-11], but there are some reports of
extrameningeal complications [11-13].
The incidence of meningococcal disease in Taiwan was
below 0.001 from 1980 to 1987, and re-emerged in 2000
with a rate of 0.07/105 population. In 2001 there was a
further increase in incidence (0.19/105) [14]. Serogroup B
was the most common and W135 was secondmost pre-
dominant, which is different from other country [1,14].
To determine the clinical characteristics and outcome of
patients with serogroup W135 and non-W135 meningo-
coccal disease in Taiwan, a nationwide study was con-
ducted from January 1, 2001, through December 31,
2003. The relationship between N. meningitidis sero-
groups with respect to patient characteristics, clinical
manifestations, and outcome was assessed. The factors
associated with mortality in meningococcal disease were
also investigated.
Methods
Case reporting and microbiology laboratory procedures
In the National Notifiable Disease Surveillance System in
Taiwan, patients with sudden onset of fever, headache,
nausea, vomiting, stiff neck, petechial rash with pink mac-
ules, accompanied by delirium, coma or shock; or Gram-
negative diplococci were found in smear of cerebrospinal
fluid by Gram-stain should be reported to the Center for
Disease Control (CDC), Taiwan as suspected cases of
invasive meningococcal disease within 24 hours. In addi-
tion to the routine examination and culture in individual
hospital, blood and/or cerebrospinal fluid of the suspect
N. meningitidis would be sent to the bacteriology labora-
tory of Taiwan CDC at room temperature as soon as pos-
sible for bacteria culture and serogrouping. If N.
meningitidis is isolated and the patient had compatible
clinical symptoms and signs, the patient would be justi-
fied as a confirmed case of invasive meningococcal dis-
ease. If N. meningitidis is isolated in bacteriology
laboratory of individual hospital, the isolate would be
sent to Taiwan CDC laboratory. The identification of all
isolates were reconfirmed at Taiwan CDC using conven-
tional biochemical methods [15]. Serogrouping using the
agglutination test (Murex Biotech Ltd, Dartford, UK) and
standard grouping sera for capsular types A, B, C, X, Y, Z,
and W-135 was also performed at Taiwan CDC.
Epidemiological investigation
Within 48 hours since suspected case reported, the staffs
at local Health Bureau will conduct the case investigation,
to understand the detail travel history and identify every
single close contact during the 2 weeks before disease
onset. Patients or their family who have traveled abroad 3
months before onset were recorded. If any close contact
develops fever, the person would be send to hospital
immediately for examination, sampling and treatment.
The close contacts with no related symptoms would
receive prophylaxis as soon as possible.
Clinical information collection
From January 2001 through December 2003, case-record
forms designed for collection of detailed clinical data were
send to and filled out by those physicians who reported
the laboratory-confirmed cases. The information pro-
vided by the case-record forms included patients' history,
symptoms and signs on admission, laboratory findings on
admission, clinical course, treatment, outcome, and neu-
rological findings at discharge. Patients were categorized
as having either meningitis or pure bacteremia (the latter
was defined as pure bacteremia if patients had neither
meningitis nor abnormal cerebrospinal fluid analysis).
Bacteremia without sepsis was defined as growth of N.
meningitidis on blood agar in patients with fever but no
signs of meningococcemia or meningitis [16]. Pneumonia
was defined if consolidation or pleural effusion was seen
on chest radiograph. Arthritis was present if the classic
inflammatory signs of redness, swelling, heat and pain in
the joint(s) were found.
Statistics
The association of the following parameters (serogroup,
age, sex, clinical category, initial symptoms and signs, and
hemogram value) with mortality was analyzed. Statistical
analyses were performed using SPSS software, version
10.0 (SPSS, Inc., Chicago, Ill, USA). The Chi-square test
was used to assess the statistical significance of difference
in the epidemiologic data, clinical manifestations, and
outcome between serogroup W135 and non-W135 cases.
Logistic regression was used to find the factors associated
with attributable death.
Results
Patient characteristics and risk factors
From January 2001 through December 2003, there were
115 cases of laboratory confirmed invasive meningococ-
cal disease reported to Taiwan CDC. The most commonBMC Infectious Diseases 2006, 6:7 http://www.biomedcentral.com/1471-2334/6/7
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serogroup was serogroup B (47.8 %, n = 55), followed by
serogroup W135 (26.1%, n = 30), serogroup Y (14.8 %, n
= 17), nongroupable (5.2%, n = 6), serogroup C (3.5%, n
= 4), and serogroup A (2.6 %, n = 3). The differences in
age, sex distribution, living area, travel history, and case
fatality rate between those with serogroup W135 and non-
W135 meningococcal infections are shown in Table 1.
Compared with patients infected by other serogroups of
meningococci, patients with serogroup W135 were older.
The median age of patients with serogroup W135, Y, oth-
ers and B were 22, 19, 11, and 8, respectively. Serogroup
W135 occurred more frequently in older patients (i.e.,
20–54 years; 50.0% vs. 25.9%, P = 0.015), while non-
W135 serogroup infections occurred more commonly in
patients younger than 10 years (83.3% vs.  55.2%, P  =
0.005). In adult patients older than 16 years old, the per-
centage of immunocompromised patients (cancer, steroid
use, and organ failure) in serogroup W135 was not differ-
ent from non-W135 group. There was no difference in the
history of traveling abroad of patients or their household
contacts with serogroup W135 or non-W135 (P > 0.05).
No patients or their household contacts had traveled to
Mecca and Medina in Saudi Arabia for the Hajj. No epi-
demic outbreaks or case clusters were reported during the
study period, except for two patients with serogroup B
who were from one family and had definitely been
exposed to each other.
Compared with patients infected by serogroup B menin-
gococci, patients with non-serogroup B were older
(median age: non-serogroup B vs. serogroup B: 20 vs. 8
years old). Non-serogroup B patients occurred more in the
age group "10–19" and "20–54" years (P < 0.05), while
serogroup B infections occurred more commonly in the
age group younger than 10 years (52.7% vs. 23.3%, P =
0.002). There were more military personnel in non-sero-
group B than serogroup B (20.0% vs. 7.3%, P = 0.049).
Comparison clinical features between patients with 
serogroup W135 and non-W135
Complete detailed clinical information was available on
77% (88/115) of patients with confirmed meningococcal
disease. The age and serogroup distribution were not dif-
ferent between groups having and lacking complete infor-
mation. The frequency of presenting symptoms, signs,
and laboratory findings of the 88 patients are shown in
Table 2. These 88 included 41 with serogroup B, 21 with
W135, 15 with Y, 3 with C, 2 with A, and 6 with non-
groupable meningococci. Fifty (56.8%) out of 88 cases
had meningitis, and 38 (43.2%) had pure bacteremia
without meningitis, including 7 cases with bacteremia
without sepsis, 6 with pneumonia, and 3 with arthritis.
Patients with serogroup W135 disease tended to have
pure bacteremia without meningitis (52.4% vs. 40.3%;
OR: 1.6; 95%CI: 0.6–4.4) and less meningitis than the
non-W135 patients, but the difference did not achieve sta-
tistical significance. Patients infected with serogroup
W135 were more likely to have pneumonia (23.8% vs.
1.5%; OR: 20.6; 95%CI: 2.3–189.0; p = 0.003). The initial
presenting symptoms, signs (Table 2), interval between
onset of symptoms and the first visit to the doctor, and
interval between initial presentation and treatment with
the first antibiotic did not differ between W135 and non-
W135 patients. Subgroup analysis of meningitis patients
showed those with serogroup W135 were less likely to
have cerebrospinal fluid white cell count higher than
1000/ml. Of the 50 patients with meningitis, 62% (31)
had positive blood culture.
Table 1: Epidemiological data of patients with serogroup W135 and Non-W135 meningococcal disease.
Parameter W135 N = 30 Non-W135 N = 85 Total N = 115 P
Male 17(56.7) 44(51.8) 61(53.0) 0.644
Age distribution 0.030
<1 year 5(16.7) 22(25.9) 27(23.5) 0.306
1–9 years 0(0) 16(18.8) 16(13.9) 0.011
10–19 years 5(16.7) 11(12.9) 16(13.9) 0.759
20–54 years 15 (50.0) 22(25.9) 37(32.2) 0.015
55 years 5(16.7) 14(16.5) 19(16.5) 0.980
College & high school students 1(3.3) 5(5.9) 6(5.2) 1.000
Military personnel 5(16.7) 11(12.9) 16(13.9) 0.759
Living area 0.385
North Taiwan 14(46.7) 43(50.6) 57(49.6)
Central Taiwan 5(17.2) 21(24.4) 26(22.6)
South Taiwan 10(34.5) 16(18.6) 26(22.6)
East Taiwan 1(3.4) 5(5.8) 6(5.2)
With travel abroad history a 1(3.3) 8(9.4) 9(7.8) 0.442
Deaths 6(20.0) 22(25.9) 28(24.3) 0.519
NOTE. Data are no. (%) of patients, unless otherwise indicated.
a Any patients and/or their family with travel abroad history 3 months before disease were recorded.BMC Infectious Diseases 2006, 6:7 http://www.biomedcentral.com/1471-2334/6/7
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Outcome analysis
In outcome analysis, W135 patients tended to have more
intubations (42.9% vs. 23.9; OR: 2.4; 95%CI: 0.9–6.7; p =
0.09) and shock (52.4% vs. 31.3%; OR: 2.4; 95%CI: 0.9–
6.5; p = 0.08), but the difference did not reach statistical
significance.
Twenty-two percent (19/88) of the patients died and their
deaths were attributed to meningococcal infection. Fifteen
(79%) of these occurred within the first 48 hours of pres-
entation. By univariate analysis, the following factors were
associated with death attributed to meningococcal dis-
ease: pure bacteremia without meningitis, altered mental
status, WBC count of < 10,000/mm3, thrombocytopenia
(platelet < 100,000/mm3), initial systolic blood pressure
< 85 mmHg, and purpura or petechia at time of presenta-
tion to the hospital (p < 0.05) (Table 3). Using a multivar-
iate regression analysis model, after adjusting for age, pure
bacteremia (OR: 76.7, P < 0.001), altered mental status
(OR: 44.2, p < 0.001), and petechia or purpura at presen-
tation (OR: 6.4, P = 0.031) were associated with increased
risk of mortality (Table 3). Using either a univariate or
multivariate analysis model, serogroup was not found to
be a significant risk factor for mortality.
Discussion
This nationwide study of meningococcal disease in Tai-
wan focused on the sporadic occurrence of serogroup
W135 meningococcal disease. W135 serogroup
accounted for 26% of all meningococcal disease in Tai-
wan, and its prevalence is second only to that of serogroup
B. During the 1990s, N. meningitidis W135 represented
Table 2: Clinical manifestations, laboratory data, and outcome of 88 meningococcal disease patients with completed case records: 
serogroup W135 versus non-W135.
Feature W135 (n = 21) Non-W135 (n = 67) Total (n = 88) P
No underlying disease 16(76.2) 53(79.1) 69(78.4) 0.768
Underlying disease of cancer 2(9.5) 4(6.0) 6(6.8) 0.626
Steroid use 2(9.5) 2(3.0) 4(4.5) 0.240
Disease classification
Meningitis 10(47.6) 40(59.7) 50(56.8) 0.329
Bacteremia without meningitis 11(52.4) 27(40.3) 38(43.2) 0.329
Bacteremia without sepsis 2(9.5) 5(7.5) 7(8.0) 0.670
With pneumonia 5(23.8) 1(1.5) 6(6.8) 0.003
With arthritis 1(4.8) 2(3.0) 3(3.4) 0.563
Presentation
Presentation ≤1 day after symptom onset 12 (57.1) 45 (67.2) 57 (64.8) 0.402
Presentation days (mean ± SD) 1.9 ± 2.4 1.7 ± 3.0 1.8 ± 2.9 0.810
Fever 17(81.0) 58(86.6) 75(85.2) 0.501
Sore throat 6(28.6) 16(23.9) 22(25.0) 0.665
Cough 12(57.1) 29(43.3) 41(46.6) 0.267
Myalgia and/or arthragia 5(23.8) 18(26.9) 23(26.1) 0.781
Nausea and/or vomiting 8(38.1) 35(52.2) 43(48.9) 0.258
Headache 7(33.3) 26(38.8) 33(37.5) 0.651
Petechia and/or purpura 6(28.6) 26(38.8) 32(36.4) 0.395
Altered mental status 8(38.1) 31(46.3) 39(44.3) 0.511
Seizures 2(9.5) 5(7.5) 7(8.0) 0.670
Laboratory data
WBC count < 10,000/mm3 10(47.6) 26(38.8) 36(40.9) 0.474
Platelet < 100,000/mm3 6(28.6) 22(32.8) 28(31.8) 0.714
Cerebrospinal fluida
WBC count >1000/mm3 3/10(30.0) 29/40(72.5) 32/50(64.0) 0.024
WBC count 100–1000/mm3 5/10(50.0) 8/40(20.0) 13/50(26.0) 0.101
WBC count <100/mm3 2/10(20.0) 3/40(7.5) 5/50(10.0) 0.258
Protein > 300 mg/dl 4/9(44.4) 11/36(30.6) 15/45(33.3) 0.454
Glucose < 10 mg/dl 5/9(55.6) 18/35(51.4) 23/44(52.3) 1.000
Days from presentation to antibiotics use (mean ± SD) 0.7 ± 1.0 2.2 ± 5.0 1.8 ± 4.4 0.200
Outcome
Shock 11(52.4) 21(31.3) 32 (36.4) 0.080
Intubation 9 (42.9) 16(23.9) 25(28.4) 0.092
Attributable death 4(19.0) 15(22.4) 19(21.6) 1.000
Death within 48 hours 2(9.5) 13(19.4) 15(17.0) 0.293
NOTE. Data are no. (%) of patients, unless otherwise indicated. WBC: white blood cells.
a Cerebrospinal fluid data were analyzed in meningitis patients only.BMC Infectious Diseases 2006, 6:7 http://www.biomedcentral.com/1471-2334/6/7
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less than 5% of all reported N. meningitidis in the UK,
France, and the United States (1, 17–18). Taiwan is not a
Muslim country and less than 40 persons per year are Hajj
pilgrims from Taiwan. No case had contact with Hajj pil-
grims in this series and analysis of the geographic distribu-
tion and timing of our serogroup W135 meningococcal
disease cases did not suggest an epidemiologic link to Hajj
pilgrims. The nasopharyngeal carrier rate of N. meningi-
tidis was 2.3% in a nationwide surveillance from military
recruits in Taiwan in 2001, and serogroup W135 consti-
tuted 15.2% [Taiwan CDC, unpublished data].
From pulsed-field gel electrophoresis and multilocus
sequence typing genotyping in Taiwan CDC, serogroup B
isolates in Taiwan were derived from several distinct line-
ages, but isolates of serogroup A, serogroups W135 and C,
and serogroup Y, respectively, belonged to ST-7, ST-11,
and ST-23 clones [19]. All our serogroup W135 meningo-
coccal strains in Taiwan available for analysis in 2001–
2002 belonged to ST-11/ electrophoretic type-37 com-
plex, and they were apparently introduced before the Hajj
pilgrimage outbreak [19]. And multilocus variable-
number tandem repeat analysis with better genotyping
discrimination power also showed that there were no a
major epidemic N. meningitidis strain circulating in the
country [Chiou CS, et el, unpublished data]. Our basic
epidemiological data and the results of genotyping
method by Chiou CS et al do not suggest that the 2000-
Hajj epidemic directly lead to the sporadic cases of sero-
group W135 meningococcal disease in Taiwan.
Few published papers discuss the clinical characteristics of
serogroup W135 meningococcal disease, and all focus on
cases caused by the epidemic strain [3,4]. But these studies
[3,4] did not report finding more W135 than non-W135
patients who were older and in the 20–54 year-old age
group. In case series from Europe and Saudi Arabia,
patients 1–10 years-old accounted for nearly 50% of all
cases of serogroup W135 meningococcal disease [4,20].
The cause of shift in the age distribution for W135 cases in
our series was not clear. Meningococcal disease due to
uncommon serogroups such as X, Y, Z, W135, has been
reported associated with complement deficiency [21]. In
our meningococcal patients older than 16 years old with
complement 50 level and C3a level available (31/
62,50%), serogroup W135 did not have more patients
with low complement 50 and C3a level than serogroup B
(28.6%; 4/14 vs. 47.1%; 8/17)(Lin CY, unpublished
data). In adult patients elder than 16 years old, only 4
patients (28.6%) of serogroup W135 meningococcal dis-
ease had an underlying immunocompromising disease
(cancer, steroid use, and organ failure etc) and were not
different from non-W135 group. Our study showed that
83.3% of serogroup W135 disease and 76.7% of non-
serogroup B occurred in patients older than 10 years – an
age group in which the disease is potentially preventable
by use of the current quadrivalent vaccine. In Taiwan, the
current policy is to recommend meningococcal vaccina-
tion for people travelling to an endemic country, or for
use in controlling outbreaks in crowded settings such as a
school or military establishment.
If continued bacteriologic surveillance showed the rapid
clonal spread of non-serogroup B of meningococcus espe-
cially in the special population such as college students or
Table 3: Significant factors associated with attributable death by univariate and multivariate analysis.
Factors Univariate OR (95% CI) P Multivariate* OR (95% CI) P
Age > 16 0.4(0.1–1.1) 0.081
Male Sex 2.6(0.9–7.6) 0.067
Pure bacteremia 11.4(3.0–43.2) <0.001 76.7(8.8–672.0) <0.001
Serogroup W135 0.8(0.2–2.8) 0.746
Serogroup B 0.8(0.3–2.2) 0.658
Steroid use 3.9(0.5–30.0) 0.186
Malignancy 0.7(0.1–6.5) 0.762
Any underlying disease 0.7(0.2–2.3) 0.573
Fever>40°C 0.4(0.1–3.6) 0.433
Hypothermia < 36°C 3.8(1.0–14.0) 0.050
Diarrhea 1.8(0.4–9.0) 0.474
Nausea or vomiting 1.1(0.4–3.0) 0.883
Myalgia or arthragia 0.7(0.2–2.2) 0.543
Altered mental status 7.0(2.1–23.6) 0.001 44.2(5.7–340.8) <0.001
Purpura or petechia 4.2(1.4–12.2) 0.008 6.4(1.2–34.8) 0.031
WBC < 10,000/mm3 6.0(1.9–18.7) 0.002
Platelet < 100,000/mm3 5.7(1.9–16.8) 0.002
Systolic BP < 85 mmHg 5.2(1.5–17.4) 0.008
*Logistic regression after adjusting for age (forward Wald method).BMC Infectious Diseases 2006, 6:7 http://www.biomedcentral.com/1471-2334/6/7
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military personnel, the policy of public meningococcal
vaccination should be reevaluated.
In the Saudi Arabian study by Lingappa JR et al, compar-
ing patients with the epidemic strain of serogroup W135
and those with serogroup A [3], the former were less likely
to have meningitis than the latter [3]. Similarly, we found
a statistically nonsignificant trend toward more pure bac-
teremia without meningitis among patients with sporadic
W135 disease, compared to patients with non-W135 dis-
ease. Our finding that more pneumonia and less CSF
inflammatory cells in patients with W135 meningitis than
in patients with non-W135 meningitis was similar to find-
ings in France that the predominant extrameningeal dis-
eases (such as pneumonia, septic meningococcal arthritis
and pericarditis) occurred predominantly in patients with
W135 disease [10-13]. However, the use of a different def-
inition, and failure to use PCR as diagnostic tool may have
resulted in less association between arthritis and W135 in
our series.
Similar to previous reports [22-24], we found that pure
bacteremia without meningitis, altered mental status,
peripheral white cell counts less than 10,000/mm3,
thrombocytopenia < 100,000/mm3, initial systolic blood
pressure < 85 mmHg, and purpura or petechiae on admis-
sion were factors associated with mortality in patients
with meningococcal disease. There are several scoring sys-
tems developed for assessing the prognosis and mortality
of meningococcal disease [22-25], Glasgow Meningococ-
cal Septicemia Prognostic Score is a good example of a
clinical prediction tool for assessing the mortality of
meningococcal disease [22,23]. Most of those scoring sys-
tems are based on easily available clinical and laboratory
parameters such as differences in age distribution, period
between onset of disease and admission, absence of men-
ingitis, presence of widespread skin lesions, hypotension,
metabolic acidosis, normal C-reactive protein level,
absence of leukocytosis, presence of thrombocytopenia,
and hypofibrinogenemia [22-25]. However, some of the
above factors (e.g., C-reactive protein and fibrinogen lev-
els) were not routinely checked in our cases.
Previous studies that included only a low percentage of
patients with serogroup W135 meningococcal disease
could not comment on the influence of W135 on out-
come [23-25]. Our present series, with a higher percentage
of patients with serogroup W135 disease, showed no dif-
ference in case-fatality rates between patients with W135
and patients with non-W135. Lingappa JR et al [3] also
found no difference in the case fatality rate between
patients with serogroup W135 and serogroup A in Saudi
Arabia, but more patients with W135 needed intensive
care. There was a statistically insignificant trend toward
more shock and intubation in patients with W135 com-
pared with those with non-W135 in our series.
Conclusion
In conclusion, sporadic W135 infections accounted for a
substantial proportion of meningococcal disease in Tai-
wan from 2001 through 2003 and do not appear to be
Hajj-related. More patients age 20–54 years, and not
younger, developed the disease in Taiwan. The clinical
features of W135 and non-W135 meningococcal disease
were similar except that patients with W135 disease were
more likely to have extrameningeal involvement such as
pneumonia. Independent predictors of mortality
included bacteremia without meningitis, altered mental
status, and petechiae or purpura on admission.
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